Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Carcinoma, Medullary × Omeprazole × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 6 Breast Neoplasms 3 Zollinger-Ellison Syndrome 1 Triple Negative Breast Neoplasms 1 Stomach Ulcer 1 Solid Tumours 1 Solid Tumor 1 Pharmacokinetics of MDV3100 1 Ovarian Neoplasms 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell, Marginal Zone 1 Hodgkin Disease 1 Healthy Adult Participants 1 Esophagitis, Peptic 1 Carcinoma, Medullary 1 Breast Neoplasms, Male 1 Advanced Solid Tumours 1 Advanced Solid Tumors 1 Advanced Solid Tumor 1 Adult Solid Neoplasm 1

Interventions

vandetanib 2 cabozantinib 2 Trastuzumab 2 Magnetic Resonance Spectroscopy 2 Everolimus 2 veliparib 1 vatalanib 1 tumor necrosis factor-alpha, CNGRC fusion protein, human 1 tipifarnib 1 temsirolimus 1 sargramostim 1 pentetreotide 1 mercaptoundecahydrododecaborate 1 gallium Ga 68 dotatate 1 fludarabine 1 cixutumumab 1 Vinorelbine 1 Temozolomide 1 Specimen Handling 1 Sirolimus 1 Semaxinib 1 Salts 1 Ranitidine 1 Paclitaxel 1 Omeprazole 1 Octreotide 1 Nivolumab 1 Interleukin-12 Subunit p35 1 Interleukin-12 1 High-Energy Shock Waves 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01539655 2017-05-02

Vandetanib

Sanofi

Phase 1 Completed

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡